Method of treating cystitis

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to methods of treating cystitis of various origins. Increasing the clinical effectiveness and reducing a probability of recurrences are ensured by administering therapeutically active and gel preparations possessing a high adhesion to urothelium walls. The method involves instilling sodium alginate in the form of Colegel gel containing the therapeutically active preparations dioxidine, lidocaine, deoxyribonucleate, sodium hyaluronate in a therapeutically effective amount with the instillation procedure suggested to be performed according to the schedule specified depending on the cystitis origin. If observing chronic bacterial recurrent cystitis, the following schedule is presented: instillations of Colegel-ADL from the 1st to 10th therapeutic day daily, instillations of Colegel-DNK-L from the 11th to 20th therapeutic day every second day, 2-month instillation of Colegel-Hyal once a week. Treating radiation and interstitial cystitis requires the following therapeutic schedule: instillations of Colegel-ADL from the 1st to 20th day, while Colegel-DNK-L and Colegel-Hyal are instilled once twice a week from the 21st to 56th day alternated every second day. The presented therapeutic schedules using the given therapeutically active preparations enabling relieving pain, reducing a rate and a length of recurrent cystitis.

EFFECT: using these therapeutic schedules is high-efficient and safe.

1 ex

 

The invention relates to medicine, namely to methods of treatment of recurrent bacterial cystitis.

There is a method of treatment of cystitis, including intravesical introduction viscoelastic buffered physiological solution of sodium hyaluronate (P. Century. glebocka, Y., alyayev, H. K. Hajiyev, Mirkin J. B. Use of hyaluronic acid in the treatment of chronic cystitis. EF. Urology. 5/2011, pp. 30-35).

The disadvantage of this method is that the solution of sodium hyaluronate has no lasting effect, because the drug has a weak adhesion to urothelia bladder and soon after the introduction out of the body, requires repeated quite complex (it will only nurses and painful for the patient's procedure.

There is a method local, including intravesical therapy of chronic cystitis (RF Patent No. 2270678, IPC AC 31/495), which consists in the intravesical administration of 0.5% solution dioksidina with the simultaneous introduction of "Enterosgel".

The disadvantage of this method is the poor adhesion of the injected solution dioksidina to the walls of urothelia, as well as the need to introduce "Enterosgel" that can reduce the concentration of dioksidin.

The task of the invention is to remedy these disadvantages, the increase of treatment efficiency and the lower the likelihood of relapse due to the introduction of therapeutically active and gel preparations, having high adhesion to the walls of urothelia.

To solve the tasks proposed in the treatment of chronic recurrent bacterial cystitis to make gel instillation of the drug, "Kregel-ADL" from 1 to 10 day treatment daily, then intelliroute "Collegel-DNA-L" from the 11th to the 20th day after day.

The proposed treatment regimen using data therapeutically active drugs can reduce pain symptoms, reduce the frequency and duration of recurrent cystitis.

The implementation of the method is demonstrated on specific clinical examples.

Example 1.

A patient, 34 years old, suffers from recurrent bacterial cystitis 20 years, the recurrence rate increased from 1-2 per year, up to 10-12 episodes a year, the intensity of relapse by the visual analogue scale was reached 7 points, period of 5-7 days. During a relapse in the General analysis of urine leukocytes were found in 30-40 p/vision, urine culture - E. coli 5*105.

Were treated by the proposed method.

In pre-emptied the bladder is introduced with a syringe through the catheter therapeutically active drugs according to the following scheme:

1-10 day - "Collegel-ADL" on the 1st instillation of 20 ml daily.

11-20 day - "Collegel-DNA-L" on the 1st instillation of 20 ml a day.

After a course of intravesical therapy for 1.5 years was not observed no recurrence of cystitis. Urinalysis: leukocytes in 1-2 p/SP. (norm), urine culture - no growth.

The proposed method was treated 21 patients. All patients after treatment by the proposed schemes reported a decrease of discomfort and burning in the urethra during the first week of treatment. Frequency of urination as a result of treatment decreased on average by 33% during the first three weeks of treatment. The number of night time urination in women is also significantly decreased on average 3 times.

During the treatment by the proposed method have stabilized glucosamine layer of patients, treatment is highly effective and safe.

A method for the treatment of chronic recurrent bacterial cystitis, including the installation of gel preparation "Collegel-ADL" from 1 to 10 day treatment every day, and then install "Collegel-DNA-L" from the 11th to the 20th day after day.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a topical composition containing a combination of natural salt or pure sodium chloride and glucose mixed in ratio 1:1-30 (wt/wt) as an active ingredient in an amount effective for treating bacterial vaginosis caused by Cardnerella vaginalis together with a pharmaceutically acceptable carrier.

EFFECT: invention provides the higher pharmacological activity.

4 cl, 4 ex, 5 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and concerns: a therapeutic agent for treating the lower urinary tract disease, wherein the agent contains a thrombin-like enzyme as a single main active ingredient; an agent for relieving the lower urinary tract pain associated with the lower urinary tract disease; a method of the treating lower urinary tract disease involving the stage of administering an effective amount of the thrombin-like enzyme.

EFFECT: group of inventions provides marginal therapeutic effects on the lower urinary tract disease.

23 cl, 6 dwg, 8 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: rehabilitation of children with chronic microbial-inflammatory urinary diseases with the low immune status is ensured by the staged rehabilitation treatment of patients in the stage of complete and partial clinical and laboratory remission. The first stage involves a complex whereat the patient is exposed to ultraviolet short-wave beams according to the standard technique including tonsils, and endonasally according to the standard technique every second day within the 16-21-day therapeutic course. That is followed by a helper stimulation of a chest by means of Helper apparatus with using 19, 20 and 21 sternal point for 3-5 minutes for each within the 7-10-day daily therapeutic course. Therapeutic exercises and phytotherapy are prescribed next with using essences, namely sage, or mint, or aniseed, or eucalypt essences, every second day within the 7-10-day therapeutic course. Thereafter, 3-4 months later at the second stage of rehabilitation, inhalations with immunopotentiating agents, namely 0.5% lysozyme, or sodium nucleinate, or aralia infusion, or ginseng infusion, or eleuterococcus infusion, or aloe extract are prescribed in the form of 10-15 minute daily procedures. The adrenal glands are stimulated with a low-frequency alternating magnetic field generated by Polus-1 stimulator, daily for 10-20 minutes within the therapeutic course of 10-20 procedures. That is followed by the helper stimulation of a thymus by means of Helper apparatus with using 19, 20 and 21 sternal point for 3-5 minutes for each within the 7-10-day therapeutic course. The patient does therapeutic exercises. At the 3rd stage 3-4 months later, the patient is subject to an extremely high frequency electromagnetic exposure covering the middle one-third of the sternum for 5-25 minutes within the therapeutic course of 8-10 procedures, daily or every second day; or the thymus helper stimulation is applied; or a splenin or interferon phonophoresis on the submandibular lymph nodes is alternated with a complex immune preparation on wings of nose with the length of exposure 2-3 minutes within the therapeutic course of 8-10 procedures daily or every second day. The complex certainly includes a halotherapy consisting in 12-25 daily session of the length of 30 minutes, a chest massage and therapeutic exercises. The final 4th stage involves cold water treatment as provided by standard techniques, helper stimulation of the sternum and feet, therapeutic massage, therapeutic exercises, swimming, pine baths or contrast shower. The length and therapeutic course are selected individually for each child.

EFFECT: higher effectiveness of the rehabilitation treatment, namely the recovery of the main disease, reduced intercurrent infections, normalised immunogram ensured by the staged rehabilitation program aiming at the non-invasive targeted effect on the immune system.

3 ex

FIELD: chemistry.

SUBSTANCE: claimed invention relates to novel compound of formula (1) or its pharmaceutically acceptable salt, possessing SNS inhibiting properties. In general formula R1 represents (1) hydrogen atom, (2) halogen atom, (3) C1-6alkyl group or (4) C1-6halogenalkyl group (whereR1 can be present in any substitutable position of benzene or pyridine ring); L represents (1) simple bond, (2) -O- or (3) -CH2O- (where L can be present in position 5 or 6 of condensed cycle); R2 represents (1) C6-10aryl group (C6-10aryl group is optionally condensed with C3-6cycloalkane), optionally substituted with substituent(s), X represents carbon atom or nitrogen atom. Other values of radicals are given in the invention formula.

EFFECT: obtaining compounds which can be used to prepare medication for treatment or prevention of such diseases as neuropathic pain, nociceptive pain, dysuria, disseminated sclerosis, etc.

19 cl, 47 tbl, 237 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely a method for preparing an agent possessing anticoagulant, hypotensive and diuretic action. The method for preparing the agent possessing anticoagulant, hypotensive and diuretic action, consisting in the fact that milled dark mullein is extracted in 60% ethanol by re-percolation in a cluster of 3 unequally batched percolators; the prepared extract is settled, filtered, boiled down and dried in a vacuum drier in the certain environment.

EFFECT: agent prepared by the above method possess pronounced anticoagulant, hypotensive and diuretic action.

4 tbl

FIELD: chemistry.

SUBSTANCE: invention relates organic chemistry and specifically to novel pyridine amide derivatives of general formula I where n equals 1; R1 and R2 together denote a residue selected from a group consisting of -CH=N-NH- and -CH=CH-N=CH-, which is bonded in any desirable direction to the parent structure or R2 and R3 together denote a residue selected from a group consisting of -CH=N-NH-; -CR28=N-NH-; -S-C(=S)-NH-; -S-CR29=N-; -N=CR30-O-; -N=CH-NH-; -N=N-NH-; -O-CH2-O-; -CH2-CH2-CH2-NH, -O-CH2-CH2-O-; -N=CH-CH=N-; -CH=CH-CH=N-, which is bonded in any desirable direction to the parent structure, or R3 and R4 together denote a -CH=N-NH- residue, which is bonded in any desirable direction to the parent structure, or R4 and R5 together denote a -CH=N-NH- residue, which is bonded in any desirable direction to the parent structure, and the rest of the residues R1, R2, R3, R4 and R5, mutually independently, in each case denote H; where R28 denotes F; Cl; Br or I; R29 and R30, mutually independently, in each case denote -NH-C(=O)-R31; -NH2; -NH-S(=O)2-R32; -NH-C(=O)-O-R33; -S-R34; where R31, R32, R33 and R34, mutually independently, in each case denote a straight or branched, saturated, unsubstituted aliphatic C1-10 residue; R6 denotes H or denotes a straight or branched, saturated, unsubstituted aliphatic C1-10 residue; R7 denotes hydrogen or -OH; R denotes -CF3; or denotes an unsubstituted tert-butyl residue; T denotes C-R35 and U denotes C-R36, V denotes N and W denotes C-R38; where R35 and R36 denote H; where R38 denotes -NR40R41; -OR42 or -SR43; where R40, R41, R42 and R43, mutually independently, in each case denote a straight or branched, saturated, unsubstituted aliphatic C1-10 residue; or denote a saturated, unsubstituted 3-, 4-, 5-, 6-, 7-, 8- or 9-member cycloaliphatic residue, or where R40 and R41 in each case together with a nitrogen atom as a ring member which binds them together, form a saturated 6-member heterocycloaliphatic residue, optionally substituted with one R57 residue, where R57 denotes a straight or branched, saturated, unsubstituted aliphatic C1-10 residue; in each case in form of corresponding physiologically acceptable salts. The invention also relates to a method of producing a compound of formula I, a medicinal agent based on the compound of formula I and use of the compound of formula I.

EFFECT: obtaining novel amide derivatives of pyridine, useful in treating vanilloid receptor 1 mediated diseases.

25 cl, 1 tbl, 18 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to pharmaceutical compositions for treating urination disturbance that is a syndrome manifested by frequent urination, urinary incontinence, urine retention, etc. The pharmaceutical composition contains an anticholinergic preparation that is diphenyl-acetic acid tropine ester, and preparations of the other mode of action, including Tamsulosin hydrochloride or calcium channels or baclofen in the form of prolonged release tablets or capsules or transdermal dosage forms (gels, ointments or plasters).

EFFECT: using the invention enables extending the range of therapeutic agents and improving the clinical effectiveness in urination disturbances accompanying a variety of common urological, neurological and gynaecological conditions alongside with improving the quality of life in patients with the urination disturbance.

4 cl, 24 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, specifically to a drug preparation possessing diuretic activity. The drug preparation possessing diuretic activity, comprising a liquid or dry extract of common St. John's wort and standard sugar/sorbitol syrup, in certain proportions of the ingredients.

EFFECT: drug preparation possesses complex diuretic and antiseptic action and has no side effects.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound selected from a group consisting of: 4-[(2-{[(2S)-2-fluoropropyl](pyridin-2-ylsulfonyl)amino}-4,5-dimethylphenoxy)methyl]benzoic acid, 4-[(2-{[(2R)-2-fluoropropyl](pyridin-2-ylsulfonyl)amino}-4,5-dimethylphenoxy)methyl]benzoic acid, 4-{[(6-{[(2R)-2-fluoropropyl](pyridin-2-ylsulfonyl)amino}-2,3-dihydro-1H-inden-5-yl)oxy)methyl} benzoic acid, 4-[(5-chlor-2-{[(2S)-2-fluoropropyl](pyridin-2-ylsulfonyl)amino}-4-methylphenoxy)methyl]benzoic acid, 4-[(5-chlor-2-{[(2R)-2-fluoropropyl](pyridin-2-ylsulfonyl)amino}-4-methylphenoxy)methyl]benzoic acid, 4-[(2-{[(2R)-3-fluor-2- methylpropyl](pyridin-2-ylsulfonyl)amino}-4,5-dimethylphenoxy)methyl]benzoic acid, 4-[(2-{[(2S)-3-fluor-2- methylpropyl](pyridin-2-ylsulfonyl)amino}-4,5-dimethylphenoxy)methyl]benzoic acid, 4-{[(6-{[(2R)-2-fluorobutyl](pyridin-2-ylsulfonyl)amino}-2,3-dihydro-1H-inden-5-yl)oxy)methyl} benzoic acid, 4-{[(6-{[(2S)-2-fluorobutyl](pyridin-2-ylsulfonyl)amino}-2,3-dihydro-1H-inden-5-yl)oxy)methyl}benzoic acid, 4-[(5-chlor-2-{[(2R)-2-fluoropropyl] (pyridin-3-ylsulfonyl)amino}-4-methylphenoxy)methyl]benzoic acid, 4-[(5-chlor- 2-{[(2S)-2-fluoropropyl](pyridin-3-ylsulfonyl)amino}-4-methylphenoxy)methyl] benzoic acid, 4-[(2-{[(2S)-2-fluoropropyl](pyridin-3-ylsulfonyl)amino}-4,5-dimethylphenoxy)methyl]benzoic acid, 4-[(2-{[(2R)-2-fluoropropyl](pyridin-3-ylsulfonyl)amino}-4,5-dimethylphenoxy)methyl] benzoic acid, 4-{[(6-{[(2S)-2-fluoropropyl](pyridin-3-ylsulfonyl)amino}-2,3-dihydro-1H-inden-5-yl)oxy)methyl} benzoic acid and 4-{[(6-{[(2R)-2-fluoropropyl](pyridin-3-ylsulfonyl)amino}-2,3-dihydro-1H-inden-5-yl)oxy)methyl}benzoic acid, or a pharmaceutically acceptable salt thereof. These compounds have an EP1 receptor antagonist effect and may be used for treating the dysfunction pollakiuria.

EFFECT: preparing the sulfonamide compounds with a strong EP1 receptor antagonist effect.

23 cl, 24 tbl, 31 ex

Amide compound // 2479576

FIELD: chemistry.

SUBSTANCE: compounds exhibit antagonistic activity towards the EP4 receptor, which enables use thereof as an active ingredient in a pharmaceutical composition for treating chronic kidney disease or diabetic nephropathy.

EFFECT: high efficiency of the compounds.

27 cl, 228 tbl, 86 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to thoracic surgery, and can be used to close defects of the lower one-third of the oesophagus. A laparotomy and a sagittal diaphragmotomy are performed. The oesophageal wall defect is closed with a single-layer uninterrupted absorbable mass suture. The suture is started from the proximal end of the defect with the first knot tightened into the oesophageal lumen. A fundoplication cuff is created with covering the suture with the stomach. One of the gastric walls is fixed by interrupted sutures surrounding the closed oesophageal defect to form a cavity between the closed oesophageal defect and the gastric wall. The cavity is filled with Coletex ADL hydrogel tissue. The fundoplication cuff is fixed by interrupted sutures circularly to the diaphragm. The pleural spaces, mediastinal and subphrenic space are drained.

EFFECT: method provides reducing the time of recovery, reducing a probability of postoperative complications and faster rehabilitation by forming the reliable sutures, long bactericidal effect on the suture area, dividing the pleural space and abdominal cavity.

1 ex

FIELD: medicine.

SUBSTANCE: method involves the endoscopically controlled introduction of Coletex-D gel into a fistulous passage from the oesophagus until filled completely. The following exposure to a laser light at wavelength 0.66 mcm, output power 15-45 mWt/cm2 covers a fistulous passage mouth for 5-7 minutes to be repeated in the same mode every second day. The course of the laser light exposure makes 8-10 procedures.

EFFECT: method provides the adequate therapy requiring no abdominal surgeries and the lower risk of chest and abdominal injuries, the shorter rehabilitation period by improved sealing of the fistulous passage, fistula healing, reduced inflammatory process.

2 ex

FIELD: medicine.

SUBSTANCE: method for preparing involves forming a dispersion of water-soluble sodium alginate and particles with gelling calcium ions; water-soluble sodium alginate is introduced into calcium carbonate directly in the concentration of 0.08-0.12 wt %, and adding organic acid specified in 2,4-hexanediene, para-toluic, 4-propyloxybenzoic in an amount of 0.12-0.36 wt % with the ratio of calcium salt and the above acids of 2:3, 1:2, 1:3 respectively. The prepared alginate system is settled to form a gel matrix at room temperature that is followed by γ-sterilisation.

EFFECT: hydrogel matrixes hold the shape stability after the γ-sterilisation procedure, possess the excellent tactile properties being soft and elastic, provide the targeted prolonged drug delivery.

6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the pharmaceutical industry, in particular to a peroral pharmaceutical composition, which contains polysaccharides from platyclades of Opuntia Ficus Indica, an extract of Olea Europeae leaves, alginate and sodium bicarbonate in a specified ratio. Components of the composition described above act with respect to reduction of gastroesophageal reflux.

EFFECT: peroral pharmaceutical composition is intended for the prevention and treatment of gastroesophageal reflux and GERD.

4 cl, 9 tbl, 6 dwg

FIELD: medicine.

SUBSTANCE: what is described is a composition for preparing a dosage form having prolonged action and containing drug preparations with radioprotective activity: Mexidol, Dimexidum, urea, methyluracil, sodium deoxyribonucleate, as well as a water-soluble polymer or a mixture of polymers specified in a group: sodium alginate, pectin, chitosan salt, water, and a substance or a mixture of substances having antiradical properties, and specified in a group consisting of sea buckthorn, bilberry, glycerol, polyethylene glycol, with the following ratio of ingredients, wt %: thickening polymer 1.0-8.0; pharmacological agent in a therapeutically effective amount; substances having antiradical properties 0.5-6.0; distilled water - the rest.

EFFECT: higher degree of intact tissue protection against radiation damages.

8 ex, 2 tbl

FIELD: chemistry, pharmacology.

SUBSTANCE: composition contains 0.8-2.0 wt % of sodium hyaluronate, 1-3 wt % of sodium alginate and distilled water to 100 wt %. Composition possesses prolonged adhesion to glycosamine-glycan urothelium layer and creates barrier for adhesion of bacteria to affected tissues by covering urothelium with biopolymer film.

EFFECT: composition ensures expressed therapeutic effect, considerably reduces edema of urinary bladder walls, stops or considerably reduces pain syndrome, considerably reduces number of cystitis recurrences.

3 ex

FIELD: medicine.

SUBSTANCE: there are performed beam therapy, intracavitary therapy and chemotherapy. For 5-7 days before the beginning of the radiation, Colagel-Beta with 1 β-interleukin 20 ml is introduced into a vaginal tube daily. Each session of the intracavitary therapy is preceded by introducing Colegel with 5-fluoruracil 20-25 ml into an uterine cavity and exposed for 30-40 minutes. Besides, from the beginning of the beam therapy 40-50 minutes after the radiation session, sodium alginate gel 20 ml containing methyluracil, dimethyl sulphoxide and hydrocortisone are introduced into a rectum and a bladder in a therapeutically effective amount. 5-10 procedures are performed.

EFFECT: providing faster regression of the tumour, reducing the rate and severity of radiation injuries of the rectus and bladder adjacent with the uterus with no risk of severe systemic toxic manifestations, including in senior patients with comorbid inoperable diseases and extended tumours.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to a method for preparing a therapeutic hydrogel material involving mixing an aqueous solution of sodium alginate and a drug preparation, dispersing a cross-linking agent that is presented by calcium sulphate in glycerol in the concentration of 0.8-2.5%, mixing the dispersion with the prepared mixture of sodium alginate with the drug preparation in ratio 1-2:4-6, placing the prepared product into a tiling pattern and keeping it till form-stable, conducting gamma sterilisation; the formation process involves the mechanical stability measurements with the diametral compression of the formed hydrogel; the hydrogel is considered to be formed once a thickness of the formed hydrogel varies with the diametral compression by 10-30%.

EFFECT: invention provides the wider medical variation of the drug concentrations, preparing high-thixotropy soft hydrogel materials (tablets) easy to administer, including through rectum, preparing the materials that preserve its all their physical-technical and mechanical properties after the gamma sterilisation along with the sterility.

4 cl, 10 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, more specifically to physiotherapy, otorhinolaryngology, audiology, rehabilitation medicine, and may be used for the physiotherapeutic body exposure in the diseases developed in cerebral and cervical human tissues and organs, such as perceptive hearing loss, siagonantritis, eustachitis, temporomandibular dysfunctional pain syndrome, odontogenous or rhinogenous trifacial neuralgia, Bell's palsy etc. For this purpose, a concha of auricle is exposed to electric current by introducing an electrode into an ear to contact a cavity and cup of concha tightly. Besides, the above are exposed to electric current through an electrode placed into a nasal passage. The electrodes are wrapped in a wet tissue made of a non-woven material with surface density 160-180 g/m2 containing a polymer layer of sodium alginate containing a drug preparation or a mixture thereof. The exposure is generated by direct electric current with its intensity to be gradually increased from 1 to 5 mA. The procedures are sequential at first from one side, and then from the other side. The exposure time makes 10-15 minutes from each side. The therapeutic course is 8-12 daily procedures.

EFFECT: appropriate prescription of the drug preparations enables the method providing the evident analgesic and anti-inflammatory action, activation of the tissue immune processes, improved innervation within the exposure region, recovered locomotor function of the temporomandibular joint and masticatory muscles, higher contractive activity of the muscles of expression, reduced development of any negative responses and complications ensured by the combined action of direct electric current and prolonged action of the pharmacological preparations in the presented tissues.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly oncology and surgery, and may be used in treating rectal cancer. That is ensured by teleirradiation, oral administration of capecitabine, intrarectal administration of metronidazole, local SHF hyperthermia followed by a surgical intervention. Capecitabine is administered 2000 mg/m2 from the 1st to 14th days. Metronidazole 10 g/m2 is intrarectally administered on the 3rd and 5th therapeutic days as a part of a composite mixture having the following proportions, wt %: metronidazole 12-22, sodium alginate 4-6, dimethylsulphoxide 2, distilled water up to 100. The 5-hour exposure of metronidazole is followed by a session of teletherapy. The local SHF hyperthermia at temperature 41-45° for one hour follows a session of teletherapy on 3rd, 4th and 5th therapeutic days. The surgical intervention is conducted 4 weeks after the completion of the preoperative therapy.

EFFECT: method provides ensuring complete therapeutic pathomorphism of the tumour in 25% of patients, reducing toxic and post-therapeutic complications, as well as enables conducting sphincter-preserving surgical interventions.

3 ex

FIELD: medicine.

SUBSTANCE: composition 16-21ml consisting of a mixture of therapeutic preparations: Dona glucosamine sulphate 3.0 ml; ChondroGuard, or Mucosatum, or Chondrolon chondroitin sulphate - 2.0 ml; Alflutop 2.0 ml; Actovegin 4.0-5.0 ml; glucocorticosteroids Depo-Medrol 1.0-2.0 ml in the concentration of 40 mg/ml, or Diprospane 1.0-2.0 ml in the concentration of 7 mg/ml, or Metipred 1.0-2.0 ml in the concentration of 62.5 mg/ml; vitamins B1, B6, B12 Combilipen 2.0 ml, or Milgamma 2.0 ml, or Neurobion 3.0 ml; 95% or 70% ethanol 2.0-4.0 ml, is administered into a pathologically changed region. That is immediately followed by exposing the pathologically changed region and adjoining segments to a session of A shock-wave therapy in the following mode: pressure 1.2 - 4.0 bar, frequency 7-12 Hz, beat quantity 8000-14000 for 20-40 minutes. The complex procedures are performed within the course of 1-6 times every 7-10 days.

EFFECT: method enables the direct exposure on the pathologically changed region to achieve the optimum concentration of drug preparations therein with avoiding systemic prescription and preventing a risk of side effects.

3 tbl, 2 ex

Up!